Medtronic’s (MDT) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Medtronic (NYSE:MDT) in a report released on Thursday, MarketBeat Ratings reports. Needham & Company LLC currently has a $120.00 target price on the medical technology company’s stock.

MDT has been the topic of a number of other reports. Barclays reaffirmed an “overweight” rating and set a $118.00 target price on shares of Medtronic in a research note on Wednesday, February 18th. Leerink Partners reissued an “outperform” rating and issued a $119.00 price target on shares of Medtronic in a research note on Tuesday, March 10th. Daiwa Securities Group reduced their price target on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Citigroup began coverage on Medtronic in a report on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 price objective on the stock. Finally, CICC Research began coverage on Medtronic in a research report on Friday, January 30th. They issued an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

Medtronic Stock Down 0.2%

Shares of NYSE:MDT opened at $87.72 on Thursday. Medtronic has a 52-week low of $79.55 and a 52-week high of $106.33. The stock has a market cap of $112.62 billion, a P/E ratio of 24.43, a PEG ratio of 2.26 and a beta of 0.71. The business has a fifty day moving average of $95.99 and a two-hundred day moving average of $96.52. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts expect that Medtronic will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be paid a $0.71 dividend. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.2%. Medtronic’s payout ratio is 79.11%.

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.26% of the company’s stock.

Institutional Investors Weigh In On Medtronic

Large investors have recently bought and sold shares of the stock. Delos Wealth Advisors LLC acquired a new position in shares of Medtronic during the second quarter worth about $27,000. Corundum Trust Company INC purchased a new stake in shares of Medtronic during the third quarter worth approximately $27,000. Lodestone Wealth Management LLC acquired a new stake in Medtronic in the fourth quarter valued at approximately $27,000. Anfield Capital Management LLC lifted its stake in Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the last quarter. Finally, Monetary Solutions Ltd purchased a new position in Medtronic in the fourth quarter worth approximately $27,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Needham reaffirmed a Buy on MDT with a $120 price target, highlighting confidence in Medtronic’s multi‑year growth story and tuck‑in acquisition strategy, which supports upside expectations. Needham Reiterates Buy
• Positive Sentiment: FDA expanded the indication for the OmniaSecure defibrillation lead to allow placement in the left bundle branch area, broadening use for conduction‑system pacing and potentially increasing adoption in cardiac device procedures. OmniaSecure FDA Approval
• Positive Sentiment: Medtronic expanded its pain portfolio via a distribution agreement with Merit Medical to offer the FDA‑cleared ViaVerte basivertebral nerve ablation system — a minimally invasive, implant‑free option for chronic low‑back pain that can drive incremental sales in pain management. ViaVerte Distribution Deal
• Positive Sentiment: Market commentary reiterates the planned spin‑off of Medtronic’s high‑growth diabetes unit later this year — a strategic move investors view as value‑unlocking by creating a pure‑play diabetes company and a leaner core medtech business. Spin-Off Thesis
• Neutral Sentiment: Analyst coverage and articles (Zacks, TipRanks, others) largely frame recent news as mixed but keep consensus sentiment constructive — analysts expect multi‑year EPS growth despite the recent charge. Analyst Commentary
• Negative Sentiment: Medtronic cut FY‑2026 guidance after taking a charge tied to MiniMed approval and private equity considerations; this near‑term hit to earnings outlook is the primary reason shares are down as investors reassess short‑term profitability. Guidance Cut / MiniMed Charge

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).